Format

Send to

Choose Destination
Reproduction. 2017 Oct;154(4):R81-R97. doi: 10.1530/REP-17-0322.

Implications of microRNA dysregulation in the development of prostate cancer.

Author information

1
Laboratorio de Oncología Molecular y Nuevos Blancos TerapéuticosInstituto de Biología y Medicina Experimental (IBYME), CONICET, Buenos Aires, Argentina adesiervi@dna.uba.ar.
2
Laboratorio de Oncología Molecular y Nuevos Blancos TerapéuticosInstituto de Biología y Medicina Experimental (IBYME), CONICET, Buenos Aires, Argentina.

Abstract

MicroRNAs (miRNAs) are non-coding small RNAs that target mRNA to reduce protein expression. They play fundamental roles in several diseases, including prostate cancer (PCa). A single miRNA can target hundreds of mRNAs and coordinately regulate them, which implicates them in nearly every biological pathway. Hence, miRNAs modulate proliferation, cell cycle, apoptosis, adhesion, migration, invasion and metastasis, most of them constituting crucial hallmarks of cancer. Due to these properties, miRNAs emerged as promising tools for diagnostic, prognosis and management of cancer patients. Moreover, they come out as potential targets for cancer treatment, and several efforts are being made to progress in the field of miRNA-based cancer therapy. In this review, we will summarize the recent information about miRNAs in PCa. We will recapitulate all the miRNAs involved in the androgen pathway and the biology of PCa, focusing in PCa initiation and progression. In particular, we will describe the miRNAs associated with cell proliferation, cell cycle and apoptosis in PCa, as well as invasion, adhesion and metastatic miRNAs. We will revise the recent progress made understanding the role of circulating miRNAs identified in PCa that might be useful for PCa patient stratification. Another key aspect to be discussed in this review is miRNAs' role in PCa therapy, including the miRNAs delivery.

PMID:
28878093
DOI:
10.1530/REP-17-0322
[Indexed for MEDLINE]

Supplemental Content

Full text links

Icon for Sheridan PubFactory
Loading ...
Support Center